Clinical Research Study

 
News Articles for Clinical Research Study top ^
All evaluable CLL patients treated with once daily TGR-1202 at 800 mg exhibited significant nodal reductions with 3 of 4 patients achieving > 50% nodal partial response TGR-1202 appears well tolerated;  no hepatic toxicity observed; limited GI side effects with no Grade 3 or greater GI toxicity Activity correlates with higher drug exposure; linear pharmacokinetics observed through 1200 mg QD dose cohort Half-life in excess of 24 hours supports once daily dosing 1200mg QD cohort cleared without defining an MTD; dosing continues at 1800 mg NEW YORK, Dec.
Sign-up for TG Therapeutics, Inc. Announces Presentation of Encouraging Clinical Activity of TGR-1202 in an Ongoing Multi-Center Phase I Clinical Study investment picks
Second graph under Other Results subhead, second sentence should read: The event rate of severe hypoglycemia was also lower in the AFREZZA-Gen2 group (8.05 events per 100 subject-months) than in the insulin aspart group (14.45 events per 100 subject-months); however, this difference was not statistically significant (p=0.1022) (sted The event rate of severe hypoglycemia was also lower in the AFREZZA-Gen2 group (8.05 events per subject-month) than in the insulin aspart group (14.45 events per subject-month); however, this difference was not statistically significant (p=0.1022)). The corrected release reads: MANNKIND REPORTS POSITIVE DATA FROM A PHASE 3 CLINICAL STUDY OF AFREZZA IN PATIENTS WITH TYPE 1 DIABETES MannKind Corporation (Nasdaq: MNKD) today announced positive preliminary results from Study 171, a Phase 3 clinical study of AFREZZA ®
Sign-up for CORRECTING and REPLACING MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 1 Diabetes investment picks
2014/3/20
New Analysis Explores Interactions Between Clinical Risk Factors Used in Pre-surgical Assessment AUSTIN, Texas , March 20, 2014 /PRNewswire/ --  (Nasdaq: VRML)   --
Sign-up for American Journal of Obstetrics & Gynecology Publishes New Clinical Study on the Relationship Between Imaging and OVA1® in Assessing Risk of Ovarian Cancer investment picks
2014/3/25
SALT LAKE CITY, March 25, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results from seven clinical studies will be presented at the upcoming American College of Medical Genetics (ACMG) annual meeting, which will be held Mar.
Sign-up for Myriad to Present Seven Clinical Studies at the Annual Clinical Genetics Meeting investment picks
2013/8/8
http://media.marketwire.com/attachments/201207/48809_SareptaTherapeutics.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1041095&ProfileId=051205&sourceType=1 CAMBRIDGE, MA --
Sign-up for Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology investment picks
2013/8/14
MannKind Corporation (Nasdaq: MNKD) today announced positive preliminary results from Study 175, a Phase 3 clinical study of AFREZZA ® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind’s next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler), in patients with type 2 diabetes.
Sign-up for MannKind Reports Positive Data from a Phase 3 Clinical Study of AFREZZA in Patients with Type 2 Diabetes investment picks
2014/2/27
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0930094001&sourceType=1 http://media3.marketwire.com/logos/20131114-adherex-lg.jpg RESEARCH TRIANGLE PARK, NORTH CAROLINA --
Sign-up for Adherex Announces Sodium Thiosulfate Clinical Study Update investment picks
2014/4/3
Product has fast track designation by FDA Potential to be the first topical treatment approved for painful diabetic neuropathy RALEIGH, N.C. , April 3, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy.
Sign-up for BioDelivery Sciences Announces Enrollment of the First Patient in a Phase 3 Clinical Study of Clonidine Topical Gel for Painful Diabetic Neuropathy investment picks
2013/9/9
Zalicus Inc. (Nasdaq Capital Market:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has initiated a Phase 1b clinical study with Z944, its novel oral T-type calcium channel blocker, in an experimental clinical model of neuropathic pain using Laser-Evoked Potentials (LEP). Results from the LEP study are expected in the fourth quarter 2013.
Sign-up for Zalicus Initiates Phase 1b Clinical Study of Z944, Its Novel, Oral, T-type Calcium Channel Blocker, for the Treatment of Pain investment picks
2014/2/18
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company’s first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, D o uble-Masked, Randomized, Controlled, Efficacy a nd S afety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control  I n Subjects With Moderate to S evere Dry Eye Disease). EBI-005, the Company’s most advanced product candidate generated using its AMP-Rx platform, is a novel, topically administered Interleukin-1 (IL-1) receptor blocker currently in development for the treatment of dry eye disease and allergic conjunctivitis.
Sign-up for Eleven Biotherapeutics Initiates Pivotal Phase 3 Clinical Study with EBI-005 in Dry Eye Disease investment picks
http://media.marketwire.com/attachments/201010/14430_helixbiopharmalogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1055047&ProfileId=051205&sourceType=1 AURORA, ON --
Sign-up for Helix BioPharma Corp. Initiates Enrollment for Fifth Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 investment picks
2014/3/26
EWING, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Celator Pharmaceuticals, Inc.   (Nasdaq:CPXX) , a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection as a treatment for patients with higher risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), who are refractory to or in relapse after hypomethylating agent (HMA) therapy.
Sign-up for Celator(R) Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Relapsed/Refractory Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients investment picks
2013/11/18
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance.
Sign-up for Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance investment picks
2013/7/17
Pompano Beach, July 17, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ:DSKX) , a leading developer of personal care products, announced today clinical results of a study showing that its Spectral.DNC-S containing a compound sourced as a byproduct of pine production is effective in the promotion of healthy hair and in the cessation of thinning hair in males.
Sign-up for DS Healthcare Announces Results from New Clinical Study investment picks
2013/9/6
Study to investigate Trovagene's non-invasive cancer monitoring technology using cell-free DNA from urine samples SAN DIEGO , Sept.
Sign-up for Trovagene collaborates with USC in clinical study evaluating cancer monitoring technology investment picks
2013/9/3
Esperion Therapeutics, Inc. (Nasdaq: ESPR) , a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or “bad cholesterol”). The study demonstrated that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10 mg of atorvastatin (p<0.0001). ETC-1002 was well tolerated over eight weeks of treatment when added to a statin and no serious adverse events (SAEs) were reported.
Sign-up for Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia investment picks
An experimental heart valve developed by Medtronic Inc. (MDT) appeared to help reduce the rate of death and major stroke by 40.7% among patients in a large clinical trial who were unable to undergo traditional surgery.
Sign-up for Medtronic Heart Valve Succeeds in Large Clinical Study investment picks
2013/10/29
By Joseph Walker An experimental heart valve developed by Medtronic Inc. (MDT) appeared to help reduce the rate of death and major stroke by 40.7% among patients in a large clinical trial who were unable to undergo traditional surgery.
Sign-up for Medtronic Heart Valve Succeeds In Large Clinical Study investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Clinical Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Clinical Research Programs  |  Next: Clinical Results